Ixsys Inc. said Monday that it has entered into a researchagreement with Bristol-Myers Squibb for developingmonoclonal antibodies directed against certain tumor antigens.The collaboration is an extension of an earlier feasibility studyby the two companies.

Under this agreement, Ixsys of San Diego will use itsproprietary protein engineering technology for identificationand optimization of MAbs for use in fighting certain cancers,said James R. Tretter, Ixsys' president and chief executiveofficer.

(c) 1997 American Health Consultants. All rights reserved.